Trialssemaglutidetirzepatidesarcopeniaclinicaltrials.gov

Istanbul trial tracks sarcopenia risk in non-diabetic obese adults on GLP-1s

The prospective descriptive study measures muscle mass, strength and physical performance at baseline and three months after starting therapy.

By Priya Raman · Science Reporter

Oct 5 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07858864, sponsored by Istanbul Saglik Bilimleri University and recruiting since May 30, 2026, assesses sarcopenia risk in non-diabetic obese adults beginning GLP-1 receptor agonist treatment.
02Prescribers weighing lean-mass loss during 15-20% weight reductions on semaglutide or tirzepatide have little data in non-diabetic patients; the protocol notes existing evidence is limited and inconsistent.
03It is a descriptive single-center study with a three-month follow-up and no control arm, so it will describe associations rather than establish that the drugs cause muscle loss.

From the source

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
NCT07858864 · N/A · RECRUITING · Sponsor: Istanbul Saglik Bilimleri University · Conditions: Obesity, Sarcopenia.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07858864